Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Abstract excerpt

Non-small cell lung cancer (NSCLC) adenocarcinoma (LUAD) is a leading cause of death worldwide. Activating mutations in the tyrosine kinase domain of the oncogene epidermal growth factor receptor (EGFR) are responsible for ~10-50% of all LUAD cases. Although tyrosine kinase inhibitors (TKIs) have been effective in prolonging patient survival and quality of life, acquired resistance and disease progression are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced biosensing and bioanalysis techniques
• Share to Cancer therapeutics and mechanisms
• Share to Monoclonal and Polyclonal Antibodies Research